In recent years, phishing has undergone a significant transformation due to the integration of artificial intelligence (AI) into cybercriminals' tactics. This evolution has led to more sophisticated and harder-to-detect attacks, increasing their prevalence and effectiveness.

The biotech sector is revolutionizing health, agriculture, and science with innovations that can change the world. But with great advancements come great risks, especially when it comes to cybersecurity. Critical information from clinical trials, intellectual property, and sensitive patient data has become the perfect target for cybercriminals and their cyberattacks.

Virtual private networks (VPNs) have been the go-to solution for ensuring secure connections to corporate networks for years. However, with the rise of remote work, the adoption of multi-cloud environments, and the increase in cyber threats, companies are rethinking their access security strategies. In this context, two new technologies are gaining popularity: SASE (Secure Access Service Edge) and ZTNA (Zero Trust Network Access).

The biotechnology sector has been one of the fastest-growing industries in recent years, known for its innovation in drug development, diagnostics, and advanced therapies. However, this progress has also attracted the attention of cybercriminals. In 2023, ransomware became one of the main threats to biotechs, jeopardizing the security of critical data and operational continuity.

The food industry is undergoing a digital transformation, adopting technologies like IoT, SCADA systems, and cloud platforms to optimize its processes. However, this evolution has also increased its exposure to cyber threats that could compromise food safety, operational continuity, and business reputation.

In the fast-paced world of biotechnology, where innovation advances at a rapid pace, information security has become an unavoidable priority. Biotech companies handle extremely sensitive data: from pioneering research to genetic information of patients. Protecting these assets is not just a matter of regulatory compliance but a necessity to ensure business continuity and stakeholder trust.

The food industry has undergone rapid digital transformation in recent years. From automated production systems to supply chain management platforms, technology has improved efficiency. However, this digitalization has also made companies in the sector attractive targets for cyberattacks.

In an era where DNA turns into data, laboratories are managed in the cloud, and molecular discoveries are stored in globally interconnected servers, cybersecurity becomes a priority. As cybersecurity specialists, we at ESED have witnessed in real-time how the biotechnology industry has shifted from being an analog, closed environment to becoming one of the most digitized, distributed, and vulnerable sectors.

In the realm of corporate cybersecurity, it’s not enough to have protected systems: they must be tested. Threat detection, response capacity, and defense strength are not only measured theoretically but also practically. And this is precisely where an increasingly popular strategy among organizations focused on prevention comes into play: simulating cyberattacks through Red Team and Blue Team exercises.

Protecting genomic and research data is essential for biotechnology companies, given the value and sensitivity of the information they handle. Implementing appropriate cybersecurity strategies not only protects intellectual property but also ensures the trust of patients, investors, suppliers, and collaborators.

Corporate social media channels serve as the window to any business. They are the medium through which companies interact directly with customers in an increasingly digital environment. Social media helps humanize the business, which is often hidden behind a screen. It's also the way to promote products and strengthen a brand.

Biotech companies are a prime target for cybercriminals due to the sensitive nature of their data, which includes confidential information about research and development, intellectual property, patient data, and collaborations with other organizations.